Dezhan Healthcare Company Limited (SHE:000813)

China flag China · Delayed Price · Currency is CNY
3.620
+0.040 (1.12%)
Apr 29, 2026, 3:04 PM CST
19.08%
Market Cap 7.59B
Revenue (ttm) 396.16M
Net Income (ttm) -357.73M
Shares Out 2.10B
EPS (ttm) -0.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 38,403,715
Average Volume 33,635,030
Open 3.340
Previous Close 3.580
Day's Range 3.340 - 3.640
52-Week Range 2.940 - 5.260
Beta 0.57
RSI 59.16
Earnings Date Apr 25, 2026

About Dezhan Healthcare Company

Dezhan Healthcare Company Limited engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People’s Republic of China. The company offers atorvastatin calcium tablets, amlodipine atorvastatin calcium tablets, trimetazidine hydrochloride capsules, amiodarone hydrochloride tablets, as well as other drugs, including famciclovir tablets, azathioprine tablets, and hydroxyurea tablets and colchicine tablet. It also involved in the provision of biological peptides, industrial hemp, and medical s... [Read more]

Sector Healthcare
Founded 1980
Employees 1,054
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 000813
Full Company Profile

Financial Performance

In 2025, Dezhan Healthcare Company's revenue was 396.81 million, a decrease of -14.94% compared to the previous year's 466.49 million. Losses were -345.42 million, 1592.2% more than in 2024.

Financial Statements

News

There is no news available yet.